arrow
S

Shunichi Sugawara

sendai kousei hospital
H指数:48
被引数:2.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study

塔拉他马布在铂类化疗后的小细胞肺癌中的应用:DeLLphi-304研究中日本患者的亚组分析

2026-09-190
OAAI
Disease Kinetics and Practice Patterns in ≥4-Year Long-Term Beneficiaries of Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer

晚期非小细胞肺癌免疫检查点抑制剂≥4年长期受益者的疾病动力学与实践模式

2026-07-280
PRE
Predicting Radiation-Induced Esophagitis in Locally Advanced NSCLC Using Baseline Clinical Factors: A Model from the Japan Lung Cancer Society Integrated Phase II–III Database

基于日本肺癌协会整合的II–III期数据库,利用基线临床因素预测局部晚期非小细胞肺癌的放射性食管炎

2026-04-240
PRE
Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52

Nivolumab联合化疗和贝伐单抗治疗TASUKI-52非鳞NSCLC患者的4年预后

2026-01-290
OAAI
Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study

无放疗的帕博利珠单抗联合化疗治疗PD-L1肿瘤比例评分≥50%的局部晚期非小细胞肺癌(Evolution试验):一项多中心、单臂、Ⅱ期研究

2025-10-110
PRE
Real-world outcomes and association between immune-related adverse events and therapeutic efficacy of nivolumab plus ipilimumab in elderly patients (≥75 years) with advanced non-small cell lung cancer

真实世界结局及免疫相关不良事件与纳武利尤单抗联合伊匹木单抗在≥75岁晚期非小细胞肺癌患者中的治疗疗效关联性

2025-09-300
PRE
Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutations

EGFR激活突变阳性的非小细胞肺癌患者在接受EGFR酪氨酸激酶抑制剂治疗期间化疗的生物学影响

2025-09-160
OAAI
A case of lower respiratory tract infection caused by Pandoraea sputorum in a human T-lymphotropic virus type 1 carrier

一例由Pandoraea sputorum引起的下呼吸道感染,发生在人类T淋巴细胞病毒1型携带者中

2025-09-010
OAAI
Durvalumab plus irinotecan + cisplatin for untreated extensive-stage small cell lung cancer: REBORN, phase II study (WJOG13520L)

度伐利尤单抗联合伊立替康+顺铂用于未经治疗的广泛期小细胞肺癌:REBORN,II期研究(WJOG13520L)

2025-06-290
OA
A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC

Datopotamab Deruxtecan在EGFR突变非小细胞肺癌患者中的合并分析

2025-06-120
OAAI
Prospective Multi-Institutional Observational Study of Retreatment with Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1/PD-L1 Plus Chemotherapy: NJLCG (North Japan Lung Cancer Group) Trial 1901

前瞻性多机构观察性研究:对既往接受过抗PD-1/PD-L1联合化疗治疗的非小细胞肺癌患者进行抗PD-1/PD-L1抗体再治疗的观察研究:NJLCG(北日本肺癌研究组)试验1901

CANCERS
IF4.4
2025-05-020
OA
Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study

30天内出现皮肤疾病是接受尼妥珠单抗联合吉西他滨和顺铂治疗的肺鳞状细胞癌患者的有利预后因素:NINJA研究的亚组分析

2025-03-150
OA
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial

一线纳武利尤单抗联合铂类化疗和贝伐珠单抗治疗晚期非鳞非小细胞肺癌:TASUKI-52 III期随机试验3年随访

2025-03-010
PRE
Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in resected lung cancer: A combined analysis of phase III studies

辅助细胞毒性化疗和吉非替尼在切除肺癌中的纵向复发风险:一项III期研究的联合分析

2025-03-010
OAAI
Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK plus NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials

布加替尼在ALK TKI初治的ALK阳性晚期NSCLC患者中的疗效和安全性:ALTA-1L和J-ALTA试验的整合分析

2025-03-010
PRE
Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study

尼妥珠单抗联合顺铂和吉西他滨治疗在晚期肺鳞状细胞癌患者中诱导低镁血症的临床影响:NINJA研究的亚组分析

2025-02-140
OA